Energiekontor AG · ISIN: DE0005313506 · Research | Analyses | Ratings

Buy

Original-Research: Energiekontor AG - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to Energiekontor AG Company Name: Energiekontor AG ISIN: DE0005313506 Reason for the research: Update Recommendation: Buy from: 03.07.2024 Target price: 126,00 Euro Target price on sight of: 12 Monate Last rating change: 18.10.2022: Hochstufung von Hinzufügen auf Kaufen Analyst: Dr. Karsten von Blumenthal First Berlin Equity Research hat ein Research Update zu Energie...

+++ Corporate Insights +++- Company news, directors dealings, net short positions

Current analyst assessments

On this page you will find current analyst assessments of renowned research houses, which make their assessments on the business development of listed companies available for publication and distribution via our content partner EQS-Newswire.
Reset Filter
This might be interesting for you as well
09 August 2023 02:46PM
Buy
Original-Research: Pharming Group NV - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Pharming Group NV Unternehmen: Pharming Group NV ISIN: NL0010391025 Anlass der Studie: Q2 2023 results Empfehlung: Buy seit: 09.08.2023 Kursziel: €1.60 Kursziel auf Sicht von: 12 months Letzte Ratingänderung: - Analyst: ...
Pharming Group NV
18 July 2023 11:56AM
Buy
Original-Research: Pharming - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Pharming Unternehmen: Pharming ISIN: NL0010391025 Anlass der Studie: Update Empfehlung: Buy seit: 18.07.2023 Kursziel: €1.50 Kursziel auf Sicht von: 12 months Letzte Ratingänderung: - Analyst: Simon Scholes First Berlin Equity Re...
Pharming
18 July 2023 11:56AM
Pharming (von First Berlin Equity Research GmbH): Buy
Original-Research: Pharming - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Pharming Unternehmen: Pharming ISIN: NL0010391025 Anlass der Studie: Update Empfehlung: Buy seit: 18.07.2023 Kursziel: €1.50 Kursziel auf Sicht von: 12 months Letzte Ratingänderung: - Analyst: Simon Scholes First Berlin Equity Re...
Pharming
04 August 2020 02:46PM
Pharming Group NV (von First Berlin Equity Research GmbH): Kaufen
Original-Research: Pharming Group NV - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Pharming Group NV Unternehmen: Pharming Group NV ISIN: NL0010391025 Anlass der Studie: Q2-Ergebnisse Empfehlung: Buy seit: 04.08.2020 Kursziel: €1,80 Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: - Analyst:...
Pharming Group NV
More Pharming Group NV related information
Type Total Last Made by Go to
Equity Story 4 9th August 2023 EQS Group AG EQS
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Info
The information presented here was provided by our content partner EQS. The assessments of the analyst houses were transmitted in the original via the news service EQS-Newswire for publication via the affiliated distribution networks.
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.